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It has been proposed that retinoblastoma is ‘caused’ by two sequential mutations affecting
the RB1 gene, but this is a rather outdated view of cancer aetiology that does not take into
account a large amount of new acquisitions such as chromosomal and epigenetic altera-
tions.
Retinoblastoma remains probably the only cancer in which the rather simplistic ‘two hit’
mutational model is still considered of value, although cancer is known to be associated
with genomic and microsatellite instability, defects of the DNA mismatch repair system,
alterations of DNA methylation and hystone acethylation/deacethylation, and aneuploidy.
Moreover, as it is shown herein, the predictions made by the ‘two hit’ model, are not ful-
filled by the clinical and epidemiological data reported so far. Moreover, while the role of
mutational events in cancer has been largely questioned in the more recent literature,
no serious effort has been done to investigate the role of epigenetic alterations and aneu-
ploidy in retinoblastoma.
Through the analysis of the specialised literature and a set of original epidemiological
and biological data concerning retinoblastoma, the authors illustrate the evidences arguing
against the ‘two hit’ hypothesis and propose that epigenetic factors and aneuploidy play
central roles in the disease.
 2007 Elsevier Ltd. All rights reserved.1. Introduction
Retinoblastoma (Rb) is a tumour affecting the retina of one
(unilateral Rb) or both eyes (bilateral Rb) in children. Enucle-
ation (i.e. the surgical ablation of the affected eye), with con-
sequent blindness, still represents a common modality in the
management of the disease, even if more ‘conservative’ ap-
proaches have become increasingly practiced in recent years,
thanks to the availability of newer and more sophisticated lo-
cal treatment modalities.1
A large amount of highly specialised information on reti-
noblastoma is presently available through the Internet and
at easy reach by anyone wanting to get detailed information
on this eye tumour affecting young children.er Ltd. All rights reserved
fax: +39 577 369185.
Mastrangelo).However, the honourable purpose of spreading informa-
tion that can be invaluable for affected patients and their par-
ents, should not lead to disregarding the absolute necessity of
a strict control on the quality and reliability of the informa-
tion itself, particularly when the ‘audience’ is as large as that
of the worldwide web users.
A closer look at the information reported on retinoblas-
toma by some groups of qualified scientists in this field,
gives us the opportunity to discuss some of the statements,
concepts and ideas regarding this disease that, to our opin-
ion, are far from being definitively demonstrated and
accepted.
One example is represented by the definition of the role
of the RB1 gene in retinoblastoma. As reported in one of.
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ease ‘. . .Retinoblastoma occurs in cells that have a predis-
posing mutation of the RB1 gene’ and also: ‘...RB1 is the
only gene known to be associated with retinoblastoma’, and
finally: ‘Hereditary retinoblastoma, caused by germline (RB1)
mutations, is inherited in an autosomal dominant manner’.2
Although both the web and the current literature seem to
confirm these different views concerning the role of the
RB1 gene in retinoblastoma,3–5 it is not difficult to see that
‘association’, ‘predisposition’, and ‘causation’ are not one and
the same concept and that they cannot all be attributed to
the RB1 gene without generating a certain amount of
confusion.
What ‘predisposes’ to cancer or any other disease cannot
possibly be viewed as a ‘cause’ in itself, but rather as a favour-
ing condition or co-factor. On the other hand, the ‘association’
of a certain feature (such as a gene mutation) with a given dis-
ease, is not necessarily a proof of its role as a ‘causative’ or
‘predisposing’ factor, unless the association is 100% sensitive
(all affected patients have the mutation), 100% specific (all
non affected patients do not have the mutation), 100% accu-
rate (no false positive and false negative cases), and clinically
and biologically sound (evidence must show a close and logi-
cal relationship between the feature associated to the disease
and the disease itself).
Regarding the RB1 gene mutations, the following must be
outlined about their ‘association’ with retinoblastoma:
1. They have been reported to vary from 10–20% in some
reports6 to around 89% in others,7 using experimental pro-
cedures and selection criteria biased toward the inclusion
of a large excess of bilateral cases.7,8 Globally, RB1 gene
mutations can be found in no more than 50% (low sensitiv-
ity) of all cases, according to some of the most recent
reports9;
2. they are commonly found in a great number of non retino-
blastoma cancers9,10 such as osteosarcoma, breast, blad-
der, lung, head and neck cancer, acute leukaemia, etc.
(poor specificity);
3. as a consequence, they are neither accurate nor clinically
and biologically sound or relevant with respect to their
possible role in the genesis of retinoblastoma;
4. they do not represent the only characteristic feature of the
disease in ‘positive’ cases if we consider that:
(a) Other genes, such as Rb2 may be non expressed in
retinoblastoma;11
(b) Non structural alterations of the expression of genes
such as RASSF1A, caspase 8 and 10, HIC1, HIN-1,
which have a defined role in paediatric cancer, can
be found in at least 50% of retinoblastoma investi-
gated.12–15
Taken together, the above facts alone would have been
more than a convincing evidence, for the average unbiased
scientist, to cast at least some doubts about the role of the
RB1 gene in retinoblastoma; not so for the retinoblastoma
‘establishment’ and experts, who, in spite of all this, still per-
sist in attributing to the RB1, the roles of ‘predisposing’, ‘asso-
ciated’, and ‘causing’ factor,2 as if they were one and the same
thing, thus perpetuating, since more than three decades, agreat deal of confusion and uncertainty about this important
matter.
But other and more relevant aspects of the theory behind
the genesis of retinoblastoma (The ‘two hit’ theory),16 partic-
ularly those regarding the causative and predisposing role of
the RB1 gene in retinoblastoma, strongly deserve to be re-
viewed in the light of clinical and epidemiological evidences,
as it is shown herein.
2. Materials and methods
Clinical records of 387 patients referred to the Department
of Ophthalmology (Ocular Oncology Unit) of the University
of Siena, have been selected and analysed for the present
investigation, with emphasis on data such as laterality (uni-
lateral and bilateral disease), distribution of the age at diag-
nosis, family history, and distribution of the clinical
phenotype (unilateral/bilateral) within the ‘genetic’ groups
(‘familial’, ‘hereditary’, ‘sporadic’ retinoblastoma) of the
disease.
A literature search of the same data was also performed in
order to increase the statistical consistence and compare the
clinical evidences with the corresponding predictions made
by the ‘two hit’ theory.
Original data concerning the role and significance of
aneuploidy in retinoblastoma were supplied by two of the
authors and reported in detail in the ‘discussion’ section of
this paper.
3. Results
The central assumption of the ‘two hit’ hypothesis, formu-
lated by Knudson in 197116 is that, being retinoblastoma,
dependent on two sequential mutations affecting one and
the same gene (RB1), the variegated phenotypic expression
of the disease (i.e.: unilateral, bilateral, ‘trilateral’ retinoblas-
toma, retinoma, etc.) must be related to the different timing
between the first and the second ‘hit’ (i.e.: mutation). Knud-
son realised that his theory predicted differences in the pat-
terns of age-specific incidence between inherited and
sporadic retinoblastoma, and since the appearance of his first
article on this subject, agreement was reached, among clini-
cians and epidemiologists, on the fact that: ‘. . .About 60% of
affected individuals have unilateral RB with a mean age of
diagnosis of 24 months; about 40% have bilateral RB with a
mean age of diagnosis of 15 months. . .’.2 The 60% referred
to in the above sentence is represented by the unilaterally af-
fected patients in which both ‘hits’ involve the somatic cells
(retinoblasts); while the remaining 40% is represented by the
bilaterally affected patients in which the first ‘hit’ is inherited
through the germ cells from either affected (familial retino-
blastoma) or unaffected (‘new germline’ retinoblastoma)
parents.
The theory illustrating the relationship between the tim-
ing and the target of the first and second ‘hit’, on one side,
and the age distribution of retinoblastoma, as related to its
inherited or sporadic nature, on the other, has been further
detailed and explained in a number of publications by the
same author,17–34 and is presently a consolidated and ac-
cepted view among scientists worldwide.
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nosis as predicted by the ‘two hit’ model proposed by Knud-
son. Since the model predicts that the mean age at
diagnosis for bilateral and unilateral cases is 15 and 24
months, respectively, a ‘normal’ (bell shaped) distribution will
show two different curves, whose size and width may vary,
depending on the sample size and the spreading of values,
but substantially similar to those reported in Fig. 1.
As a matter of fact, the clinical evidence shows us a quite
different situation. On a sample of 387 patients referred to the
Department of Ophthalmology of the University of Siena, we
have found the distribution reported in Fig. 2. As it is shown
in the figure, while bilateral retinoblastoma disappears after
the age of 36 months, unilateral retinoblastoma spreads over
a much wider range, with twelve cases having an age at diag-
nosis of over 100 months (not reported in the diagram), the
latest of which had been diagnosed at the ages of 204, 481,
and 540 months (17, 40, and 45 years) respectively. This is a
quite typical distribution of the age at diagnosis for both uni-
lateral and bilateral retinoblastoma on a representative
sample.0
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Fig. 1 – The normal (hypothetical) distribution of the age at diag
retinoblastoma, with a mean age of 15 months for bilateral and
interpretation, unilateral retinoblastoma is ‘globally’ diagnosed
not represent the clinical reality.
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Fig. 2 – The age distribution curve of unilateral and bilateral ret
encompasses 227 (59.7%) unilateral and 160 (41.3%) bilateral cas
their ages at diagnosis were over 100 months.To further reinforce this view, we have selected from the
literature, series in which retinoblastoma patients were allo-
cated in groups according to the age at diagnosis,35–38 and
found that, on a total of 1160 retinoblastoma patients, 86%
of bilateral and 76% of unilateral retinoblastoma had been
diagnosed within the first 24 months of life (Table 1).
Moreover, since, according to the theory, the inheritance of
the first mutation through the germ cells leads to the develop-
ment of the bilateral phenotype in the vast majority of cases
(more than 90%), it follows that familial retinoblastoma with
unilateral disease should be exceedingly rare, i.e. much less
than the predicted 10% within the hereditary (familial +
new germline) group of retinoblastoma.
Table 2 shows that, on a group of 3581 retinoblastoma,
there is a total number of 343 (9.5%) familial cases. Within this
group, 84 patients developed unilateral retinoblastoma, a fig-
ure which represents the 23% of all familial cases.
Finally, the ‘two hit’ model assumes that every bilaterally
affected individual carries a germline mutation even in the
absence of a family history, thus behaving as an ‘initiator’
or ‘founder’, in terms of transmission of the disease. To verify21 24 27 30 33
bilateral Rb
unilateral Rb
nosis is represented for both unilateral and bilateral
24 months for unilateral disease. According to the current
later than the bilateral one. This distribution, however, does
36 39 42 45 48 54 57 66 81 84 87
unilateral Rb
bilateral Rb
inoblastoma on a sample of 387 cases. The sample
es. 12 unilateral cases are not reported in the diagram since
Table 2 – On a total of 3581 retinoblastoma, 344 (9.5%) have a positive family history for the disease (within this group, the
incidence of unilateral cases is 23%, while, according to the predictions made by the ‘two hit theory’, this percentage
should be equal to or lower than that found in the general retinoblastoma population (i.e.: 6–6.5%))
Author URb BRb Tot. Fam.U Fam.B Tot. Fam
Abramson (a) 626 905 1531 36 150 186
Gunalp (b) 441 195 636 10 24 34
Sanders (c) 282 149 431 15 38 53
Matzunaga (d) 403 196 599 11 17 28
Hadjistilianou (e) 227 160 387 11 32 43
Tot. 1979 1605 3584 83 261 344
(24%) (76%)
URb = Unilateral retinoblastoma; BRb = Bilateral retinoblastoma; Fam.U = Familial unilateral (retinoblastoma); Fam.B = Familial bilateral (reti-
noblastoma). (a) J. Paediatr. Ophthamol. & Strabismus, 1985, (b) Ophthalm. Genet., 1996, (c) Br. J. Ophthalmol., 1988, (d) Hum. Genet., 1990, (e)
Eur. J. Cancer, 2007.
Table 1 – Bilateral retinoblastoma diagnosed on or before the age of 2 years (24 months) (by the age of 24 months, 306/377
(81%) bilateral and 553/729 (76%) unilateral retinoblastoma have already been diagnosed)
URb BRb Tot. u 6 1y b 6 1y u 6 2y b 6 2y
Pendergrass (a) 54 14 68 23 13 38 14
Tamboli (b) 166 54 220 93 48 125 53
Sanders (c) 282 149 431 55 91 249 123
Hadjistilianou (d) 227 160 387 72 121 146 148
Tot. 729 377 1106 233 225 553 306
URb = Unilateral retinoblastoma; BRb = Bilateral retinoblastoma; u 6 1y = Unilateral retinoblastoma diagnosed on or before the age of 1 year (12
months); b 6 1y = Bilateral retinoblastoma diagnosed on or before the age of 1 year (12 months); u 6 2y = Unilateral retinoblastoma diagnosed
on or before the age of 2 years (24 months).
(a) Arch. Ophthalmol., 1980, (b) Arch. Ophthalmol., 1990, (c) Br. J. Ophthalmol, 1988, (d) Eur. J. Cancer, 2007.
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seven patients who, being affected by bilateral (four cases) or
early unilateral retinoblastoma (three cases), had to carry,
according to the currently accepted views, a new germline
mutation and hence to be the ‘founders’ of a new series of
hereditary retinoblastoma, with a predictable 50% of affected
offspring. These seven patients globally generated nine chil-
dren of which only one developed a unilateral retinoblastoma
(the child of a unilaterally affected patient).
4. Discussion
It has been proposed by Knudson, that retinoblastoma is
‘caused’ by two sequential mutations affecting the RB1 gene
(16). This is a rather outdated view of cancer aetiology which
does not take into account a large amount of heavy argu-
ments against it, as well as an extraordinary number of new
acquisitions.
Genomic instability,39 microsatellite instability,40 and de-
fects of the DNA mismatch repair system,41 as well as altera-
tions of DNA methylation42–46 and hystone acethylation/
deacethylation,47–52 not only have been found to be involved
in the genesis of cancer, but also and more importantly, have
largely contributed to the view of cancer as an epigenetic53,54
rather than a genetic disease.55 As more recently reported,56
cancer appears to begin with epigenetic alterations in stem
cells, thus implying that epigenetic (or non mutational) loss
of gene expression comes more commonly before any muta-
tions in cancer.57,58Also, Duesberg and colleagues59–66 have heavily argued
against the somatic mutation theory by definitely demon-
strating that none of the predictions made by that theory is
fulfilled by the evidence,67 thus excluding any possible
involvement of somatic mutation, and finally demonstrating
and highlighting the fundamental role of aneuploidy in the
genesis and progression of cancer.68–70
Aneuploidy is a common feature in the majority of solid
human cancers, and several tumour cell lines show chromo-
some instability (CIN). This leads to a condition in which the
tumour phenotype is the result of the altered dosage of thou-
sands of structural and regulator genes. It is currently as-
sumed that aneuploidy drives carcinogenesis through
mutations in specific genes whose altered function causes
chromosome instability.71
A remarkable feature of retinoblastoma, at this regard, is
that loss or inactivation of Rb protein (pRb) has been associ-
ated to aneuploidy and centrosome amplification in human
cells, thus underlying the role of this protein in the processes
that regulate both chromosomal stability and centrosome
homeostasis. Inactivation of pRb promotes aneuploidy,72
probably by uncoupling cell cycle progression from mitotic
and centrosome control.73 Correct duplication of centro-
somes is very important for mitotic spindle organisation
and equal chromosome distribution to daughter cells. Centro-
some duplication is coordinated with DNA replication
through a pathway that requires pRb. Phosphorylation of
pRb, releases E2F and leads to CDK2 activation which, through
the association with cyclins E/A, is necessary for centrosomes
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amplification that in turn increases the frequency of aberrant
mitoses (multipolar spindles) and chromosome segregation
errors (aneuploidy).74–76
As it has been recently showed, the acute pRb loss induces
centrosome amplification and aneuploidy in murine primary
fibroblast, thus suggesting a direct link between pRb status,
centrosome amplification and chromosomal instability.77
Similarly, human papillomavirus type 16 (HPV-16) E7 onco-
protein rapidly induces aberrant centrosome and centriole
duplication and aneuploidy78 in human cells. Moreover, upon
release from mitotic block, normal human pRb-deficient
fibroblasts generate aneuploid cells with supernumerary cen-
trosomes by expressing the HPV16-E7 protein; these cells ac-
quire the capability to grow in an anchorage-independent
manner as tumour cells do, thus indicating that aneuploidy
is an initial mutational step in cell transformation. Interest-
ingly, HPV-DNA has been found in some cases of retinoblas-
toma, thus confirming a possible role of HPV viral proteins
E6 and E779 in the genesis of this cancer.
From the above evidences it seems reasonable to conclude
that pRb dysfunctions could drive aneuploidy and then can-
cer following several alternative pathways not necessarily
encompassing gene mutation. Unfortunately, in spite of such
an amount of evidence against the somatic mutation theory
and in favour of epigenetic/CIN causation in cancer, retino-
blastoma has remained, since 1971, probably the only tumour,
in the entire constellation of human cancer, to be blamed
upon only two mutations affecting one and a single gene.
But even if one would ignore the above advances in the
understanding of cancer aetiology and pathogenesis, the clin-
ical and epidemiological evidences supplied herein, clearly
illustrate the flaws of the ‘two hit’ theory and its related
predictions.
As it has been shown, the prediction according to which
there must be a difference in the age of incidence of unilateral
and bilateral retinoblastoma is essentially based on the inap-
propriate, incorrect, and artful use of a statistical measure-
ment, such as the ‘mean’, applied to the distribution of the
age at diagnosis for retinoblastoma.
Albert Einstein once said: ‘If the facts don’t fit the theory,
change the facts!’ and the impression here is that, on this
specific aspect, facts have been changed to a large extent, to
fit the theory.
It is clear, looking at the age distribution of retinoblastoma
in Fig. 2, that, while the calculation of the ‘mean’ can be ap-
plied to the bilateral cases, its application to the unilateral
ones, would lead to biased results. In fact, it is a well known
and consolidated opinion, among statisticians, that the mean
is a measure exceedingly sensitive to the extreme values, and
as such much less reliable than the median in representing
highly skewed distributions,80 such as the one reported in
the diagram for unilateral retinoblastoma. It is not by chance
that, when applying the calculation of the median age at diag-
nosis to our unilateral cases, we found the value of 16 months
which is very close and not significantly different from the re-
ported 15 months for the mean age at diagnosis of bilateral
retinoblastoma.
It can be concluded that there are no differences in the dis-
tributions of the age at diagnosis between unilateral andbilateral retinoblastoma, and that, as a consequence, the dif-
ferences in the timing of cellular/genetic events, as predicted
by the theory, in fact do not exist. This evidence is confirmed
by the cumulative analysis of different series reported in Ta-
ble 1 concerning the percentage of both unilateral and bilat-
eral retinoblastoma diagnosed within the first 2 years of life.
The other prediction made by the ‘two hit’ theory is that
the great majority (more than 90%) of all hereditary (familial
+ new germline) retinoblastoma, must have both eyes in-
volved (bilateral phenotype). As a consequence and comple-
ment of this prediction, it should be argued that within the
familial retinoblastoma, i.e. the hereditary group ‘par excel-
lence’, the bilateral phenotype should predominate while
the unilateral one must be exceedingly rare, accounting for
much less than the predicted 10% within the larger popula-
tion of inheritable (familial + new germline) retinoblastoma.
This is clearly not the case when considering the analysis of
different series reported in Table 2, showing that, on a group
of 343 familial retinoblastoma, belonging to a series of 3581
cases, 84, i.e.: 24%, were unilaterally affected; a figure more
than twofold higher than the predicted 10% within the hered-
itary (familial + new germline) cases and almost fourfold
higher than the predicted 6% within the general retinoblas-
toma population.
The ‘founder’ effect of the ‘new germline’ retinoblastoma,
is another prediction of the ‘two hit’ theory that deserves fur-
ther consideration. Although limited to a restricted number of
patients, our series of seven ‘new germline’ retinoblastoma,
with only one child affected by unilateral disease, on an off-
spring of nine children, represents a strong argument against
the prediction that 50% of the offspring of ‘new germline’ ret-
inoblastoma must be affected as a result of the transmission
of the disease from one of the parents.
Further consideration deserves, to conclude, the definition
of ‘sporadic’ as related to retinoblastoma and the conse-
quences of the ‘two hit theory’. A ‘sporadic’ disease is, by def-
inition, a disease occurring upon occasion or in a scattered,
isolated or seemingly random way.81 According to this defini-
tion, if one excludes the familial cases, about 90% of retino-
blastoma is ‘sporadic’ at diagnosis. However, with the
creation of the ‘perspective’ new germline group of patients,
the majority of which carry the bilateral disease phenotype,
the ‘true’ sporadic retinoblastoma group has been reduced
to about 60% essentially, but not exclusively, made of unilat-
erally affected individuals, and the adjective ‘sporadic’ has fi-
nally been used to unequivocally designate the non heritable
form of the disease. Given all of the above, one could reason-
ably distinguish between two different ‘pathogenetic’ groups;
the heritable (about 40%) and the non heritable (about 60%)
retinoblastoma, and assume that the underlying causes and
biological processes operating within the two groups are dif-
ferent and distinct. Unfortunately, the ‘unifying’ two hit the-
ory has been the source of major confusion on this topic,
since it established (and no evidence against it has been ‘offi-
cially’ admitted so far within the scientific literature) that
both the sporadic (non heritable) and the heritable disease de-
pend on one and the same process, i.e.: the loss or inactiva-
tion of the RB1 gene. How could this be possible? And also:
does this ‘unitary’ theory explain and fit the clinical and epi-
demiological reality?
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Genetics, Sampieri and Coll.,82 having found a mutation rate
of 37% in a series of Italian patients with ‘hereditary retino-
blastoma’, conclude that: ‘The mutation rate reported in the
study is quite similar to that found by other groups using
the same methodological approach’ and that, given the disap-
pointing results of this investigation, ‘. . .Other phenomena,
such as epigenetic alterations or a possible inactivation of
RB1 through mutation of non-coding sequences, may also
be invoked to explain the cause of disease in the remainder
of the patients. . .’.
We have already exposed and documented the reasons
why the whole story of the role of the RB1 gene in retinoblas-
toma is scarcely credible; but, assuming that, according to the
theory, both hereditary and non hereditary retinoblastoma
depend on mutations affecting one and the same gene, is
nothing less than absurd and in striking contrast with the
clinical and epidemiological evidences; among others, the
fact that the incidence of sporadic (unilateral) retinoblastoma
is not equally distributed throughout the world and is higher
in less industrialized countries and in less affluent popula-
tions relative to other malignancies of early childhood. In par-
ticular, non-heritable (sporadic) retinoblastoma has a higher
incidence among less affluent populations, suggesting an
association with poor living conditions and maybe an infec-
tious aetiology. This variation in incidence may be due to dif-
ferential exposure to infections or other environmental
factors in utero.83
5. ConclusionThe last 35 years of research in the field of retinoblastoma
have been dominated by the ‘two hit’ theory16 and during
this period, researchers worldwide have not only chosen
to avoid to look at any alternative explanation about its
genesis, but have also overlooked a few but substantial dis-
crepancies between the most widely accepted genetic the-
ory and the clinical/epidemiological evidence related to
retinoblastoma. It is not by chance, given this situation,
that the most important advances in retinoblastoma, have
been realised in the field of the clinical diagnosis and treat-
ment,84 with no substantial contribution of the genetic
investigations and speculations.85,86 There might be several
explanations for this curious phenomenon, including the
interests of scientific/academic lobbies, and those of the
major drug companies who presently are the main funding
resource of genetic research, worldwide, with the conse-
quent hunt for grants in search of the genetic causes of
cancer. Whatever the explanation one would adopt, we be-
lieve we should ‘go back’ to the patients and their suffer-
ings, to recover our dignity of physicians and remember
that searching for the causes of diseases in general and
cancer in particular, is not a business but the main road
leading to the sole and higher scope of our profession,
which is the cure of the sick.
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